Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Last Patient enrolled recovers in 10 days, great news

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Dec 24, 2020 11:27pm

176 Views

Post# 32182233

RE:RE:Last Patient enrolled recovers in 10 days, great news

talisman47 wrote: Where did you see that the patient was releaswed from hospital ?? I read it that the last patient was on medication for 15 days and then there was a two week follow up to analyse data. It would be fantastic if they were released 4-5 days faster than average.

Please advise. Thanks

From the NR:

"The last patient from Algernon Pharmaceuticals Inc.'s phase 2b part of its multinational phase 2b/3 human study of NP-120 (ifenprodil) for the treatment of COVID-19 has now completed treatment, as well as the required two-week follow up."

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?